Artwork

PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Player FM -팟 캐스트 앱
Player FM 앱으로 오프라인으로 전환하세요!

Manish A. Shah, MD, FASCO - Redrawing the Algorithm in Gastric and GEJ Cancers: Treatment Planning and Sequencing in the Era of Immunotherapy

59:39
 
공유
 

Manage episode 302378598 series 103590
PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Go online to PeerView.com/WNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the treatment landscape for gastric and gastroesophageal junction (GEJ) cancers continues to evolve, patients with these heterogenous and aggressive malignancies are benefiting from improved outcomes. Targeted therapies, such as anti-angiogenic agents, have had a beneficial role in the second-line gastric and GEJ cancer settings after prior fluoropyrimidine- or platinum-containing chemotherapy, while novel combinations with anti-angiogenesis agents, chemotherapy, and/or immunotherapy are showing promise in clinical trials. Furthermore, first-line therapy with an immune checkpoint inhibitor in combination with chemotherapy recently demonstrated improved outcomes over chemotherapy alone, and these data led to an FDA approval that is ushering in a new immunotherapy-based standard of care in the frontline treatment of newly diagnosed gastric and GEJ cancers. Join PeerView for an innovative, case-based activity designed to bring participants the latest data on established targeted therapies and emerging combination strategies for patients with gastric and GEJ cancers and expert guidance on incorporating treatment advances into day-to-day clinical practice. With a focus on multidisciplinary care of patients with gastric and GEJ cancers, the faculty panel will address selection and sequencing of treatment regimens along with symptom management, psychological support, nutritional considerations, and a variety of other issues that affect patients’ quality of life and outcomes. Upon completion of this accredited CE activity, participants should be better able to: Evaluate the latest clinical evidence on established targeted therapies (eg, anti-angiogenic agents) and emerging combination strategies (eg, with chemotherapy or immune checkpoint inhibitors) for patients with advanced gastric or GEJ cancer, Discuss the clinical implications of recently approved and emerging first-line treatment strategies in the settings of advanced gastric or GEJ cancer that take into consideration the potential impact of treatment selection and sequencing beyond first-line therapy, Implement a tailored approach to treatment selection and sequencing over multiple lines of therapy, based on the latest clinical evidence, current practice guidelines, and patient-, disease-, and treatment-specific factors, for patients with advanced gastric or GEJ cancer, Integrate multidisciplinary, interprofessional, and holistic care strategies that address nutritional needs, emotional and psychological concerns, treatment-related adverse events, the risk of disease progression, and other issues into the management of patients with advanced gastric or GEJ cancer.
  continue reading

329 에피소드

Artwork
icon공유
 
Manage episode 302378598 series 103590
PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Go online to PeerView.com/WNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the treatment landscape for gastric and gastroesophageal junction (GEJ) cancers continues to evolve, patients with these heterogenous and aggressive malignancies are benefiting from improved outcomes. Targeted therapies, such as anti-angiogenic agents, have had a beneficial role in the second-line gastric and GEJ cancer settings after prior fluoropyrimidine- or platinum-containing chemotherapy, while novel combinations with anti-angiogenesis agents, chemotherapy, and/or immunotherapy are showing promise in clinical trials. Furthermore, first-line therapy with an immune checkpoint inhibitor in combination with chemotherapy recently demonstrated improved outcomes over chemotherapy alone, and these data led to an FDA approval that is ushering in a new immunotherapy-based standard of care in the frontline treatment of newly diagnosed gastric and GEJ cancers. Join PeerView for an innovative, case-based activity designed to bring participants the latest data on established targeted therapies and emerging combination strategies for patients with gastric and GEJ cancers and expert guidance on incorporating treatment advances into day-to-day clinical practice. With a focus on multidisciplinary care of patients with gastric and GEJ cancers, the faculty panel will address selection and sequencing of treatment regimens along with symptom management, psychological support, nutritional considerations, and a variety of other issues that affect patients’ quality of life and outcomes. Upon completion of this accredited CE activity, participants should be better able to: Evaluate the latest clinical evidence on established targeted therapies (eg, anti-angiogenic agents) and emerging combination strategies (eg, with chemotherapy or immune checkpoint inhibitors) for patients with advanced gastric or GEJ cancer, Discuss the clinical implications of recently approved and emerging first-line treatment strategies in the settings of advanced gastric or GEJ cancer that take into consideration the potential impact of treatment selection and sequencing beyond first-line therapy, Implement a tailored approach to treatment selection and sequencing over multiple lines of therapy, based on the latest clinical evidence, current practice guidelines, and patient-, disease-, and treatment-specific factors, for patients with advanced gastric or GEJ cancer, Integrate multidisciplinary, interprofessional, and holistic care strategies that address nutritional needs, emotional and psychological concerns, treatment-related adverse events, the risk of disease progression, and other issues into the management of patients with advanced gastric or GEJ cancer.
  continue reading

329 에피소드

모든 에피소드

×
 
Loading …

플레이어 FM에 오신것을 환영합니다!

플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.

 

빠른 참조 가이드